Moundjaro significantly diminishes the likelihood of diabetes by an astonishing 94%.
Earlier on, weight loss meds were seen as miracle drugs. Initial findings showed that Semaglutid, a key ingredient, not only aided in weight loss but also lowered the chances of strokes and heart attacks. Now, another drug, Mounjaro, is making waves beyond its intended purpose. According to a study, Mounjaro, a medication from Eli Lilly, has dramatically reduced the risk of developing type 2 diabetes by 94% in adults with prediabetes, obesity, or overweight. The study involved 1032 participants where an average weight loss of 22.9% was observed in the treatment group compared to just 2.1% in the placebo group. The active ingredient in Mounjaro, marketed in the USA as Zepbound, is Tirzepatide.
As Jeff Emmick, the product development head at Lilly, put it, "Obesity is a persistent ailment that poses a significant risk of complications like type 2 diabetes for nearly 900 million adults worldwide. Tirzepatide decreased the chance of developing type 2 diabetes by 94% and resulted in sustained weight loss throughout the three-year treatment period. These findings highlight the potential positive impact of long-term treatment for individuals with obesity and prediabetes."
Lilly, along with rival Novo Nordisk, are focusing on broadening the scope of their obesity medications to treat conditions like sleep apnea and heart disease. The goal is to disassociate their weight loss injections from the perception of being just a lifestyle medication. In Germany, the medications are currently not covered by statutory health insurance.
Eli Lilly's Mounjaro, with its active ingredient Tirzepatide, has shown remarkable results in a study, leading to a 94% reduction in the risk of developing type 2 diabetes in adults with prediabetes, obesity, or overweight. Eli Lilly, in collaboration with its rival Novo Nordisk, is looking to expand the functionality of their obesity medications, aiming to treat conditions such as sleep apnea and heart disease, to move away from the perception of weight loss injections as mere lifestyle medications.
